TABLE 9.
Trough concentrations of SPR719 by dose in the MAD phase
| Dose group | Geometric LS mean trough concn (ng/ml) at daya: |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
| 500 mg × 7 days | 20.8 | 9.7 | 7.1 | 5.7 | 5.0 | 5.0 | NA | NA | NA | NA | NA | NA | NA |
| 1,000 mg × 7 days | 306 | 100 | 34.7 | 18.1 | 21.1 | 18.7 | NA | NA | NA | NA | NA | NA | NA |
| 750 mg q12h × 7 days | 2,370 | 1,510 | 1,430 | 1,300 | 662 | 406 | NA | NA | NA | NA | NA | NA | NA |
| 500 mg × 14 days | 12.4 | 8.5 | 7.2 | 7.0 | 6.6 | 7.2 | 8.6 | 5.7 | 8.1 | 11.5 | 8.3 | 5.0 | 7.4 |
| 1,000 mg × 14 days | 176 | 85 | 42.7 | 50.2 | 54.4 | 25.5 | 25.3 | 22.1 | 18.7 | 20.4 | 14.2 | 10.0 | 12.0 |
a
NA, not applicable.